GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-09-26| Trials & Approvals

ODAC Votes Against Oncopeptides’ and Spectrum’s New Oncology Drugs

by Reed Slater
Share To
The Oncologic Drugs Advisory Committee (ODAC) made its opinion clear on Thursday that the data from Oncopeptides’ Pepaxto and Spectrum Pharmaceuticals’ Pozenveo are not convincing enough to gain FDA approval. Pepaxto received accelerated approval last February to treat relapsed or refractory multiple myeloma (RRMM). Oncopeptides completed confirmatory trials for the drug that ODAC deemed did more harm than good. Spectrum sought accelerated approval for its non-small cell lung cancer (NSCLC)-focused drug, Pozenveo, which the committee did not find worthy of approval recommendation based on the presented data. 

It's free! Log in now to read

LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top